First-in-class radio-theranostic utilizes novel antibody to target B7-H3 proteins in cancer cells

MedicalXpress | 四月 01, 2026

Researchers from The University of Texas MD Anderson Cancer Center have developed a first-in-class antibody that targets a protein overexpressed in many cancer types, allowing for the creation of a new radio-theranostic treatment that brings targeted radiation directly to tumor cells. The work is published in Theranostics.